{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:51:20Z","timestamp":1791168680114,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11594-3","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:34:16Z","timestamp":1779366856000},"page":"7715-7733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advancements in microtubule targeting agents for breast cancer: design strategies and pharmacological insights"],"prefix":"10.1007","volume":"30","author":[{"given":"Paramjeet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"17","key":"11594_CR1","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","volume":"13","author":"S \u0141ukasiewicz","year":"2021","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A (2021) Breast cancer: epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review. Cancers 13(17):4287","journal-title":"Cancers"},{"issue":"3","key":"11594_CR2","first-page":"287","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q et al (2025) Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Cent 5(3):287","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"11594_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-019-0828-0","volume":"12","author":"N Li","year":"2019","unstructured":"Li N, Deng Y, Zhou L, Tian T, Yang S, Wu Y et al (2019) Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the global burden of disease study 2017. J Hematol Oncol 12(1):140","journal-title":"J Hematol Oncol"},{"issue":"3","key":"11594_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5306\/wjco.v5.i3.283","volume":"5","author":"R Shah","year":"2014","unstructured":"Shah R, Rosso K, Nathanson SD (2014) Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol 5(3):283","journal-title":"World J Clin Oncol"},{"issue":"6","key":"11594_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/95.6.448","volume":"95","author":"GS Dite","year":"2003","unstructured":"Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR et al (2003) Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 95(6):448\u2013457","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"11594_CR6","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1093\/carcin\/17.11.2279","volume":"17","author":"HS Feigelson","year":"1996","unstructured":"Feigelson HS, Henderson BE (1996) Estrogens and breast cancer. Carcinogenesis 17(11):2279\u20132284","journal-title":"Carcinogenesis"},{"issue":"8","key":"11594_CR7","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3390\/nu11081871","volume":"11","author":"JCM Godinho-Mota","year":"2019","unstructured":"Godinho-Mota JCM, Gon\u00e7alves LV, Mota JF, Soares LR, Schincaglia RM, Martins KA et al (2019) Sedentary behavior and alcohol consumption increase breast cancer risk regardless of menopausal status: a case-control study. Nutrients 11(8):1871","journal-title":"Nutrients"},{"issue":"4","key":"11594_CR8","doi-asserted-by":"publisher","first-page":"BMT51","DOI":"10.2217\/bmt-2020-0033","volume":"9","author":"S Vegunta","year":"2020","unstructured":"Vegunta S, Lester SP, Pruthi S, Mussallem DM (2020) Effects of major lifestyle factors on breast cancer risk: impact of weight, nutrition, physical activity, alcohol and tobacco. Breast Cancer Manage 9(4):BMT51","journal-title":"Breast Cancer Manage"},{"key":"11594_CR9","doi-asserted-by":"crossref","unstructured":"Thakur C, Saran U, Chen F (2025) The impact of specific environmental exposures on breast, lung, and colon cancer: advancing public health strategies for enhanced outcomes. Front Media13:1483915","DOI":"10.3389\/fpubh.2025.1483915"},{"issue":"3","key":"11594_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","volume":"5","author":"O Yersal","year":"2014","unstructured":"Yersal O, Barutca S (2014) Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol 5(3):412","journal-title":"World J Clin Oncol"},{"key":"11594_CR11","volume-title":"Cancer breast screening. Stat-Pearls","author":"DP Budh","year":"2021","unstructured":"Budh DP, Sapra A (2021) Cancer breast screening. Stat-Pearls. StatPearls Publishing, Treasure Island, FL, USA"},{"issue":"2","key":"11594_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","volume":"5","author":"Y Feng","year":"2018","unstructured":"Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L et al (2018) Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 5(2):77\u2013106","journal-title":"Genes Dis"},{"issue":"6","key":"11594_CR13","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1002\/onco.13734","volume":"26","author":"N Pramod","year":"2021","unstructured":"Pramod N, Nigam A, Basree M, Mawalkar R, Mehra S, Shinde N et al (2021) Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer. Oncologist 26(6):e943\u2013e53","journal-title":"Oncologist"},{"issue":"5","key":"11594_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.36348\/sjm.2024.v09i05.007","volume":"9","author":"M Nasir","year":"2024","unstructured":"Nasir M, Jafran SS, Paul A (2024) Inflammatory breast cancer: challenges and opportunities in the management. Saudi J Med 9(5):146\u2013153","journal-title":"Saudi J Med"},{"issue":"5","key":"11594_CR15","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","volume":"8","author":"S Al-Mahmood","year":"2018","unstructured":"Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T (2018) Metastatic and triple-negative breast cancer: challenges and treatment options. Drug delivery translational Res 8(5):1483\u20131507","journal-title":"Drug delivery translational Res"},{"issue":"16","key":"11594_CR16","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.3390\/molecules30163314","volume":"30","author":"HC Assun\u00e7\u00e3o","year":"2025","unstructured":"Assun\u00e7\u00e3o HC, Silva PM, Bousbaa H, Cidade H (2025) Recent advances in microtubule targeting agents for cancer therapy. Molecules 30(16):3314","journal-title":"Molecules"},{"key":"11594_CR17","unstructured":"Dustin P, Microtubules (2012) Springer Science & Business Media"},{"issue":"1","key":"11594_CR18","doi-asserted-by":"publisher","first-page":"1623181","DOI":"10.1155\/2022\/1623181","volume":"2022","author":"L Huang","year":"2022","unstructured":"Huang L, Peng Y, Tao X, Ding X, Li R, Jiang Y et al (2022) Microtubule organization is essential for maintaining cellular morphology and function. Oxidative Med Cell Longev 2022(1):1623181","journal-title":"Oxidative Med Cell Longev"},{"key":"11594_CR19","doi-asserted-by":"crossref","unstructured":"Knossow M, Campanacci V, Khodja LA, Gigant B (2020) The mechanism of tubulin assembly into microtubules: insights from structural studies. Iscience. 23(9):101511","DOI":"10.1016\/j.isci.2020.101511"},{"key":"11594_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fonc.2014.00153","volume":"4","author":"AL Parker","year":"2014","unstructured":"Parker AL, Kavallaris M, McCarroll JA (2014) Microtubules and their role in cellular stress in cancer. Front Oncol 4:153","journal-title":"Front Oncol"},{"issue":"11","key":"11594_CR21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2174\/1389450124666230731094837","volume":"24","author":"J Sebastian","year":"2023","unstructured":"Sebastian J, Rathinasamy K (2023) Microtubules and cell division: potential pharmacological targets in cancer therapy. Curr Drug Targets 24(11):889\u2013918","journal-title":"Curr Drug Targets"},{"key":"11594_CR22","doi-asserted-by":"crossref","unstructured":"Ritter A, Kreis N-N (2022) Microtubule dynamics and cancer. Cancers. 14(18):4368","DOI":"10.3390\/cancers14184368"},{"issue":"16","key":"11594_CR23","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.3390\/molecules25163705","volume":"25","author":"F Borys","year":"2020","unstructured":"Borys F, Joachimiak E, Krawczyk H, Fabczak H (2020) Intrinsic and extrinsic factors affecting microtubule dynamics in normal and cancer cells. Molecules 25(16):3705","journal-title":"Molecules"},{"issue":"4","key":"11594_CR24","doi-asserted-by":"publisher","first-page":"151075","DOI":"10.1016\/j.ejcb.2020.151075","volume":"99","author":"V \u010cerm\u00e1k","year":"2020","unstructured":"\u010cerm\u00e1k V, Dost\u00e1l V, Jel\u00ednek M, Libusov\u00e1 L, Kov\u00e1\u0159 J, R\u00f6sel D et al (2020) Microtubule-targeting agents and their impact on cancer treatment. Eur J Cell Biol 99(4):151075","journal-title":"Eur J Cell Biol"},{"key":"11594_CR25","doi-asserted-by":"crossref","unstructured":"Fanale D, Bronte G, Passiglia F, Cal\u00f2 V, Castiglia M, Di Piazza F et al (2015) Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol. 2015(1):690916","DOI":"10.1155\/2015\/690916"},{"issue":"3","key":"11594_CR26","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1002\/mog2.46","volume":"2","author":"X Wang","year":"2023","unstructured":"Wang X, Gigant B, Zheng X, Chen Q (2023) Microtubule-targeting agents for cancer treatment: Seven binding sites and three strategies. MedComm\u2013Oncology 2(3):e46","journal-title":"MedComm\u2013Oncology"},{"issue":"6","key":"11594_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13205-023-03636-6","volume":"13","author":"A Banyal","year":"2023","unstructured":"Banyal A, Tiwari S, Sharma A, Chanana I, Patel SKS, Kulshrestha S et al (2023) Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges. 3 Biotech 13(6):211","journal-title":"3 Biotech"},{"issue":"1","key":"11594_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/ph13010008","volume":"13","author":"EC McLoughlin","year":"2020","unstructured":"McLoughlin EC, O\u2019Boyle NM (2020) Colchicine-binding site inhibitors from chemistry to clinic: a review. Pharmaceuticals 13(1):8","journal-title":"Pharmaceuticals"},{"issue":"1","key":"11594_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12935-022-02624-9","volume":"22","author":"P Dhyani","year":"2022","unstructured":"Dhyani P, Quispe C, Sharma E, Bahukhandi A, Sati P, Attri DC et al (2022) Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int 22(1):206","journal-title":"Cancer Cell Int"},{"issue":"2","key":"11594_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/1535-7163.MCT-13-0791","volume":"13","author":"E Mukhtar","year":"2014","unstructured":"Mukhtar E, Adhami VM, Mukhtar H (2014) Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther 13(2):275\u2013284","journal-title":"Mol Cancer Ther"},{"key":"11594_CR31","doi-asserted-by":"crossref","unstructured":"Beretta GL, Cassinelli G, Rossi G, Azzariti A, Corbeau I, Tosi D et al (2025) Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies. Drug Resist Updates. 81:101223","DOI":"10.1016\/j.drup.2025.101223"},{"key":"11594_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.breast.2022.07.014","volume":"65","author":"A Vasseur","year":"2022","unstructured":"Vasseur A, Carton M, Guiu S, Augereau P, Uwer L, Mouret-Reynier M-A et al (2022) Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo) adjuvant taxanes regimen: a multicentre retrospective observational study. Breast 65:136\u2013144","journal-title":"Breast"},{"issue":"1","key":"11594_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ctrv.2009.10.001","volume":"36","author":"Y Fern\u00e1ndez","year":"2010","unstructured":"Fern\u00e1ndez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L et al (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 36(1):33\u201342","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"11594_CR34","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.3390\/cancers12113323","volume":"12","author":"SM Maloney","year":"2020","unstructured":"Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR (2020) Mechanisms of taxane resistance. Cancers 12(11):3323","journal-title":"Cancers"},{"issue":"10","key":"11594_CR35","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1096\/fj.04-3178fje","volume":"19","author":"K Shalli","year":"2005","unstructured":"Shalli K, Brown I, Heys SD, Schofield CA (2005) Alterations of \u03b2-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 19(10):1299\u20131301","journal-title":"FASEB J"},{"key":"11594_CR36","doi-asserted-by":"publisher","first-page":"107076","DOI":"10.1016\/j.bioorg.2023.107076","volume":"143","author":"M Podolak","year":"2024","unstructured":"Podolak M, Holota S, Deyak Y, Dziduch K, Dudchak R, Wujec M et al (2024) Tubulin inhibitors. Selected scaffolds and main trends in the design of novel anticancer and antiparasitic agents. Bioorg Chem 143:107076","journal-title":"Bioorg Chem"},{"key":"11594_CR37","doi-asserted-by":"crossref","unstructured":"Luque-Bolivar A, P\u00e9rez-Mora E, Villegas VE, Rond\u00f3n-Lagos M (2020) Resistance and overcoming resistance in breast cancer. Breast Cancer: Targets Therapy. 12:211\u2013229","DOI":"10.2147\/BCTT.S270799"},{"key":"11594_CR38","doi-asserted-by":"publisher","first-page":"117091","DOI":"10.1016\/j.ejmech.2024.117091","volume":"282","author":"P Pragyandipta","year":"2025","unstructured":"Pragyandipta P, Naik E, Reddy PK, Nayek A, Kantevari S, Naik PK (2025) In silico inspired design of urea noscapine congeners as anticancer agents: chemical synthesis and experimental evaluation using breast cancer cells and a xenograft mouse model. Eur J Med Chem 282:117091","journal-title":"Eur J Med Chem"},{"key":"11594_CR39","doi-asserted-by":"publisher","first-page":"117314","DOI":"10.1016\/j.ejmech.2025.117314","volume":"286","author":"W-B Liu","year":"2025","unstructured":"Liu W-B, Yang W-G, Wu J, Chen B-B, Du Y-F, Niu J-B et al (2025) Discovery of novel thienopyridine indole derivatives as inhibitors of tubulin polymerization targeting the colchicine-binding site with potent anticancer activities. Eur J Med Chem 286:117314","journal-title":"Eur J Med Chem"},{"key":"11594_CR40","doi-asserted-by":"publisher","first-page":"117139","DOI":"10.1016\/j.ejmech.2024.117139","volume":"283","author":"Q Lai","year":"2025","unstructured":"Lai Q, Wang Z, Wu C, Zhang R, Li L, Tao Y et al (2025) Design, synthesis, and antitumor evaluation of quinazoline-4-tetrahydroquinoline chemotypes as novel tubulin polymerization inhibitors targeting the colchicine site. Eur J Med Chem 283:117139","journal-title":"Eur J Med Chem"},{"key":"11594_CR41","doi-asserted-by":"crossref","unstructured":"Zhang M, Zhao B, Leng J, Zhu L, Ning M, Cao T et al (2025) Design, synthesis and biological activity of tubulin inhibitors based on the structure of deoxypodophyllotoxin. Bioorg Chem. 163:108783","DOI":"10.1016\/j.bioorg.2025.108783"},{"key":"11594_CR42","doi-asserted-by":"publisher","first-page":"108355","DOI":"10.1016\/j.bioorg.2025.108355","volume":"159","author":"B Jiang","year":"2025","unstructured":"Jiang B, Zheng Y, Xue T, Wu J, Song H, Zhou S et al (2025) Identification of selenium-containing benzamides as potent microtubule-targeting antitumor agents. Bioorg Chem 159:108355","journal-title":"Bioorg Chem"},{"issue":"11","key":"11594_CR43","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3390\/molecules29112668","volume":"29","author":"G Volpi","year":"2024","unstructured":"Volpi G, Laurenti E, Rabezzana R (2024) Imidazopyridine family: versatile and promising heterocyclic skeletons for different applications. Molecules 29(11):2668","journal-title":"Molecules"},{"key":"11594_CR44","doi-asserted-by":"crossref","unstructured":"Sarkar T, Sood M, Prassanawar SS, Jahan K, Kulkarni A, Ahirkar R et al (2025) An N-linked imidazo [1, 2-a] pyridine benzoheterobicyclic hybrid inhibits mitosis and cancer cell proliferation by targeting tubulin. Bioorg Med Chem. 128:118242","DOI":"10.1016\/j.bmc.2025.118242"},{"key":"11594_CR45","doi-asserted-by":"publisher","first-page":"115794","DOI":"10.1016\/j.ejmech.2023.115794","volume":"263","author":"W Ren","year":"2024","unstructured":"Ren W, Deng Y, Ward JD, Vairin R, Bai R, Wanniarachchi HI et al (2024) Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization. Eur J Med Chem 263:115794","journal-title":"Eur J Med Chem"},{"key":"11594_CR46","doi-asserted-by":"publisher","first-page":"117981","DOI":"10.1016\/j.bmc.2024.117981","volume":"118","author":"R Vairin","year":"2025","unstructured":"Vairin R, Tamminga C, Shi Z, Borchardt C, Jambulapati J, Bai R et al (2025) Design, synthesis and biological evaluation of 2-phenyl indole analogues of OXi8006 as colchicine site inhibitors of tubulin polymerization and vascular disrupting agents. Bioorg Med Chem 118:117981","journal-title":"Bioorg Med Chem"},{"issue":"16","key":"11594_CR47","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.3390\/ijms21165712","volume":"21","author":"N Ruwizhi","year":"2020","unstructured":"Ruwizhi N, Aderibigbe BA (2020) Cinnamic acid derivatives and their biological efficacy. Int J Mol Sci 21(16):5712","journal-title":"Int J Mol Sci"},{"key":"11594_CR48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-443-23754-6.00016-1","volume":"85","author":"K Taban","year":"2025","unstructured":"Taban K, Ilhan M, S\u00fcntar I (2025) Anticancer activities of coumarins and their structure\u2013activity relationships. Stud Nat Prod Chem 85:105\u2013142","journal-title":"Stud Nat Prod Chem"},{"key":"11594_CR49","doi-asserted-by":"crossref","unstructured":"El-Zend MA, El-Deen I, Mansour RM, Yousef TA, Alrashidi AA, Saied EM (2025) Multi-Targeted Azacoumarin\u2013cyanocinnamate hybrids induce G2\/M arrest and apoptosis via tubulin, and COX-2\/VEGFR Modulation: insights from in vitro mechanistic basis and in vivo validation. RSC Med Chem. 16(11):5574-5601.","DOI":"10.1039\/D5MD00484E"},{"key":"11594_CR50","doi-asserted-by":"crossref","unstructured":"Masci D, Puxeddu M, Colla C, Coluccia A, Santelli M, Sci\u00f2 P et al (2025) Microwave-assisted synthesis of tubulin assembly inhibitors as anticancer agents by aryl ring reversal and conjunctive approach. RSC Med Chem. 16(10):4845-4858.","DOI":"10.1039\/D5MD00406C"},{"issue":"1","key":"11594_CR51","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1039\/D4MD00541D","volume":"16","author":"MN Anisimov","year":"2025","unstructured":"Anisimov MN, Boichenko MA, Shorokhov VV, Borzunova JN, Janibekova M, Mustyatsa VV et al (2025) Synthesis and evaluation of tetrahydropyrrolo [1, 2-a] quinolin-1 (2 H)-ones as new tubulin polymerization inhibitors. RSC Med Chem 16(1):274\u2013285","journal-title":"RSC Med Chem"},{"issue":"2","key":"11594_CR52","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/biom15020210","volume":"15","author":"Z Deng","year":"2025","unstructured":"Deng Z, Li J, Zhu P, Wang J, Kong Y, Hu Y et al (2025) Quinazolinones as potential anticancer agents: synthesis and action mechanisms. Biomolecules 15(2):210","journal-title":"Biomolecules"},{"issue":"3","key":"11594_CR53","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1039\/D4MD00755G","volume":"16","author":"AR Dwivedi","year":"2025","unstructured":"Dwivedi AR, Kumar V, Prashar V, Jangid K, Kumar N, Devi B et al (2025) Synthesis and screening of novel 2, 4-bis substituted quinazolines as tubulin polymerization promoters and antiproliferative agents. RSC Med Chem 16(3):1410\u20131424","journal-title":"RSC Med Chem"},{"key":"11594_CR54","doi-asserted-by":"publisher","first-page":"140214","DOI":"10.1016\/j.molstruc.2024.140214","volume":"1321","author":"HM Abd El-Lateef","year":"2025","unstructured":"Abd El-Lateef HM, Alharbi TH, Fayad E, Katouah HA, Elsaid FG, Alsunbul M et al (2025) Novel quinolin-4-ylcarbonylhydrazine having N-(3-arylacryloyl) moiety: design, synthesis and biological evaluation as potential cytotoxic agents against MDA-MB-231 via tubulin assembly inhibition. J Mol Struct 1321:140214","journal-title":"J Mol Struct"},{"issue":"27","key":"11594_CR55","doi-asserted-by":"publisher","first-page":"21962","DOI":"10.1039\/D4RA09000D","volume":"15","author":"R Saruengkhanphasit","year":"2025","unstructured":"Saruengkhanphasit R, Chatwichien J, Ngiwsara L, Lirdprapamongkol K, Niwetmarin W, Eurtivong C et al (2025) Design, synthesis, in silico and in vitro evaluation of pyrrole\u2013indole hybrids as dual tubulin and aromatase inhibitors with potent anticancer activities. RSC Adv 15(27):21962\u201321976","journal-title":"RSC Adv"},{"issue":"8","key":"11594_CR56","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1039\/D4RA07810A","volume":"15","author":"NA Altwaijry","year":"2025","unstructured":"Altwaijry NA, Omar MA, Mohamed HS, Mounier MM, Afifi AH, Srour AM (2025) Design, synthesis, molecular docking and anticancer activity of benzothiazolecarbohydrazide\u2013sulfonate conjugates: insights into ROS-induced DNA damage and tubulin polymerization inhibition. RSC Adv 15(8):5895\u20135905","journal-title":"RSC Adv"},{"key":"11594_CR57","doi-asserted-by":"publisher","first-page":"140462","DOI":"10.1016\/j.ijbiomac.2025.140462","volume":"303","author":"MS Elkotamy","year":"2025","unstructured":"Elkotamy MS, Abdelrahman MA, Giovannuzzi S, Alkabbani MA, Nocentini A, Supuran CT et al (2025) Development of pyrazolo [1, 5-a] pyrimidine-grafted coumarins as selective carbonic anhydrase inhibitors and tubulin polymerization inhibitors with potent anticancer activity. Int J Biol Macromol 303:140462","journal-title":"Int J Biol Macromol"},{"key":"11594_CR58","doi-asserted-by":"publisher","first-page":"117486","DOI":"10.1016\/j.ejmech.2025.117486","volume":"289","author":"X Qu","year":"2025","unstructured":"Qu X, Wang Y, Xu Y, Xu L, Ye X, Cai H et al (2025) Aromatic nitroolefin with inhibition efficacy in triple-negative breast cancer cells by dual targeting RXR\u03b1 and tubulins. Eur J Med Chem 289:117486","journal-title":"Eur J Med Chem"},{"key":"11594_CR59","doi-asserted-by":"crossref","unstructured":"Ji J-W, Liu X-J, Wu J, Wang Z-Y, Niu J-B, Song J et al (2025) Discovery of novel 1, 2, 3-triazole arylamide derivatives bearing dithiocarbamate moiety as dual inhibitors of tubulin and LSD1 with potent anticancer activity. Eur J Med Chem. 296:117879","DOI":"10.1016\/j.ejmech.2025.117879"},{"key":"11594_CR60","doi-asserted-by":"publisher","first-page":"117249","DOI":"10.1016\/j.ejmech.2025.117249","volume":"285","author":"G Li","year":"2025","unstructured":"Li G, Wang M, Luo L, Tang D, Xu N, Huang R et al (2025) Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance. Eur J Med Chem 285:117249","journal-title":"Eur J Med Chem"},{"key":"11594_CR61","doi-asserted-by":"publisher","first-page":"117058","DOI":"10.1016\/j.ejmech.2024.117058","volume":"282","author":"M Zheng","year":"2025","unstructured":"Zheng M, Liu G, Han Y, Qian P, Wu M, Xiang M et al (2025) Synthesis, biological evaluation and mechanism study of a novel indole-pyridine chalcone derivative as antiproliferative agent against tumor cells through dual targeting tubulin and HK2. Eur J Med Chem 282:117058","journal-title":"Eur J Med Chem"},{"key":"11594_CR62","doi-asserted-by":"crossref","unstructured":"Elgiushy HR, Soliman ME, El-Khouly ME, Abouzid KA, Hammad SF (2025) Discovery of pyrazolo [1, 5-a] pyrimidines: synthesis, in silico insights, and anticancer activity via novel CDK2\/tubulin dual inhibition approach. Bioorg Chem. 164:108792","DOI":"10.1016\/j.bioorg.2025.108792"},{"key":"11594_CR63","doi-asserted-by":"crossref","unstructured":"Aboelez MO, Ali MAEAA, Kamel MS, Fadaly WA, Nemr MT, Ezelarab HA (2025) Novel 3, 4-diaminothieno [2, 3-b] thiophene-2, 5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity. Bioorg Chem. 163:108728","DOI":"10.1016\/j.bioorg.2025.108728"},{"key":"11594_CR64","doi-asserted-by":"crossref","unstructured":"He X, Peng Y, Liu R, Yuan W, Ye P, Wang Z et al (2025) Discovery of novel flavonoid derivatives targeting VEGFR2 and tubulin with potent anticancer efficacy. Bioorg Chem. 163:108713","DOI":"10.1016\/j.bioorg.2025.108713"},{"key":"11594_CR65","doi-asserted-by":"publisher","first-page":"108334","DOI":"10.1016\/j.bioorg.2025.108334","volume":"158","author":"UP Yadav","year":"2025","unstructured":"Yadav UP, Yaseen M, Singh S, Babu MA, Bhat MA, Kumar R et al (2025) Design and development of new substituted pyrimidine hybrids with imidazole and triazole: Exploring utility as an anticancer agent via human topoisomerase-II and tubulin inhibition. Bioorg Chem 158:108334","journal-title":"Bioorg Chem"},{"key":"11594_CR66","doi-asserted-by":"crossref","unstructured":"Dastari S, Pradhan S, Thakur V, Reddyrajula R, Chilvery S, Godugu C et al (2025) Design, synthesis and biological evaluation of spirocyclopropyl oxindole-piperazine\/morpholine-based carboxamides as potential anticancer agents. Bioorg Chem. 163:108784","DOI":"10.1016\/j.bioorg.2025.108784"},{"issue":"26","key":"11594_CR67","doi-asserted-by":"publisher","first-page":"20495","DOI":"10.1039\/D5RA01257K","volume":"15","author":"IA Seliem","year":"2025","unstructured":"Seliem IA (2025) Synthesis, cytotoxic activity, molecular docking, molecular dynamics simulations, and ADMET studies of novel spiropyrazoline oxindoles based on domino Knoevenagel\u2013Michael cyclization as potent non-toxic anticancer agents targeting \u03b2-tubulin and EGFR, with anti-MRSA activity. RSC Adv 15(26):20495\u201320512","journal-title":"RSC Adv"},{"key":"11594_CR68","doi-asserted-by":"crossref","unstructured":"Mohamed MF, Salem IM, Fouad A, Allam RM, Fadaly WA, Nemr MT et al (2025) Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase\u2013carbonic anhydrase inhibitors with potential anti-tubulin activity. Bioorg Chem. 163:108694","DOI":"10.1016\/j.bioorg.2025.108694"},{"key":"11594_CR69","doi-asserted-by":"crossref","unstructured":"Ali BS, Mohammed AF, Menon V, Ramadan WS, Simons C, Kariuki BM et al (2025) Further insights into the multitarget anticancer activity of tetrahydrocarbazole-1-amine\/5-arylidene-4-thiazolinone based hybrids. Bioorg Chem. 164:108853","DOI":"10.1016\/j.bioorg.2025.108853"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11594-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11594-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11594-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:03:41Z","timestamp":1791165821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11594-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":69,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11594"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11594-3","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors confirm that this article content has no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}